DeepMind’s Hassabis Sees AI-Designed Drug Trials This Year
This article is for subscribers only.
Google DeepMind spinoff Isomorphic Labs expects research of drugs it designed using artificial intelligence will begin this year, according to its Nobel Prize-winning chief executive officer.
“We’ll hopefully have some AI-designed drugs in clinical trials by the end of the year,” Demis Hassabis, who leads both Alphabet Inc. subsidiaries, said on a panel at the World Economic Forum in Davos. “That’s the plan.”